Sarang Abhyankar

442 total citations
23 papers, 311 citations indexed

About

Sarang Abhyankar is a scholar working on Genetics, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Sarang Abhyankar has authored 23 papers receiving a total of 311 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 10 papers in Pathology and Forensic Medicine and 4 papers in Molecular Biology. Recurrent topics in Sarang Abhyankar's work include Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (9 papers) and Melanoma and MAPK Pathways (4 papers). Sarang Abhyankar is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (9 papers) and Melanoma and MAPK Pathways (4 papers). Sarang Abhyankar collaborates with scholars based in United States, United Kingdom and Japan. Sarang Abhyankar's co-authors include Tomasz M. Beer, Bertrand Tombal, Yohann Loriot, D. Phung, Christopher Kriedt, Matthew S. Davids, Janice H. Urban, Bradley K. Taylor, Johann S. de Bono and Allen Lee Cohn and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Pain.

In The Last Decade

Sarang Abhyankar

19 papers receiving 310 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarang Abhyankar United States 11 141 105 67 66 62 23 311
Bin Yao China 12 100 0.7× 200 1.9× 34 0.5× 81 1.2× 35 0.6× 28 476
Anne Winther‐Larsen Denmark 14 226 1.6× 177 1.7× 23 0.3× 60 0.9× 53 0.9× 40 501
N. V. Lyubimova Russia 11 106 0.8× 158 1.5× 63 0.9× 106 1.6× 11 0.2× 49 419
Masako Okawa‐Takatsuji Japan 14 70 0.5× 42 0.4× 27 0.4× 80 1.2× 90 1.5× 28 478
Mercedes Noriega Germany 8 200 1.4× 47 0.4× 80 1.2× 23 0.3× 25 0.4× 18 396
Virginia Fisher United States 13 182 1.3× 172 1.6× 55 0.8× 34 0.5× 57 0.9× 26 571
S Matthes United States 10 97 0.7× 207 2.0× 31 0.5× 57 0.9× 66 1.1× 16 382
Gessamí Sánchez-Ollé Spain 8 61 0.4× 153 1.5× 53 0.8× 21 0.3× 31 0.5× 17 332
Hongli Li United States 11 54 0.4× 134 1.3× 36 0.5× 53 0.8× 217 3.5× 24 383
Steven Schoenfeld United States 10 38 0.3× 121 1.2× 156 2.3× 41 0.6× 23 0.4× 13 478

Countries citing papers authored by Sarang Abhyankar

Since Specialization
Citations

This map shows the geographic impact of Sarang Abhyankar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarang Abhyankar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarang Abhyankar more than expected).

Fields of papers citing papers by Sarang Abhyankar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarang Abhyankar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarang Abhyankar. The network helps show where Sarang Abhyankar may publish in the future.

Co-authorship network of co-authors of Sarang Abhyankar

This figure shows the co-authorship network connecting the top 25 collaborators of Sarang Abhyankar. A scholar is included among the top collaborators of Sarang Abhyankar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarang Abhyankar. Sarang Abhyankar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Rhodes, Joanna, Naleen Raj Bhandari, Dan He, et al.. (2025). Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States. Cancers. 17(15). 2592–2592.
3.
Bhandari, Naleen Raj, et al.. (2025). Continuity of care for patients with chronic lymphocytic leukemia: an analysis of real-world data. Journal of Medical Economics. 28(1). 1500–1511.
4.
Winfree, Katherine B., et al.. (2024). Pirtobrutinib in Patients with Mantle Cell Lymphoma: A Real-World Study in the United States. Blood. 144(Supplement 1). 7799–7799. 1 indexed citations
5.
Rhodes, Joanna, Naleen Raj Bhandari, Dan He, et al.. (2024). Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States. Blood. 144(Supplement 1). 5114–5114. 1 indexed citations
6.
Muehlenbein, Catherine E., Catherine C. Coombs, Nirav N. Shah, et al.. (2023). CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies. Clinical Lymphoma Myeloma & Leukemia. 23. S520–S520. 1 indexed citations
7.
Al‐Sawaf, Othman, Min‐Hua Jen, Lisa M. Hess, et al.. (2023). Pirtobrutinib <i>versus</i> venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison. Haematologica. 109(6). 1866–1873. 3 indexed citations
8.
Ryan, Christine E., Matthew S. Davids, Sarang Abhyankar, et al.. (2022). MAJIC: A Phase III Trial of Acalabrutinib + Venetoclax versus Venetoclax + Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Future Oncology. 18(33). 3689–3699. 15 indexed citations
9.
10.
11.
Davids, Matthew S., et al.. (2020). Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis. Clinical Therapeutics. 42(10). 1955–1974.e15. 19 indexed citations
12.
13.
Bryce, Alan H., Joshi J. Alumkal, Andrew J. Armstrong, et al.. (2017). Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer and Prostatic Diseases. 20(2). 221–227. 71 indexed citations
14.
15.
Saad, Fred, Cristina Ivanescu, D. Phung, et al.. (2017). Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials. Prostate Cancer and Prostatic Diseases. 20(1). 110–116. 42 indexed citations
16.
17.
Chang, Chun‐Lan, Vernon F. Schabert, Julie Munakata, et al.. (2015). Comparative healthcare costs in patients with metastatic melanoma in the USA. Melanoma Research. 25(4). 312–320. 22 indexed citations
18.
Gibney, Geoffrey T., Geneviève Gauthier, Eric Q. Wu, et al.. (2015). Treatment patterns and outcomes in BRAF V600E‐mutant melanoma patients with brain metastases receiving vemurafenib in the real‐world setting. Cancer Medicine. 4(8). 1205–1213. 19 indexed citations
19.
Taylor, Bradley K., et al.. (2007). Neuropeptide Y acts at Y1 receptors in the rostral ventral medulla to inhibit neuropathic pain. Pain. 131(1). 83–95. 40 indexed citations
20.
Abhyankar, Sarang, et al.. (2004). Right atrial dimension-pressure relation during volume expansion is unaltered by pregnancy in the rat. American Journal of Physiology-Heart and Circulatory Physiology. 288(1). H116–H120. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bin Yao Breakdown of academic impact, for papers by Anne Winther‐Larsen Breakdown of academic impact, for papers by N. V. Lyubimova Breakdown of academic impact, for papers by Masako Okawa‐Takatsuji Breakdown of academic impact, for papers by Mercedes Noriega Breakdown of academic impact, for papers by Virginia Fisher Breakdown of academic impact, for papers by S Matthes Breakdown of academic impact, for papers by Gessamí Sánchez-Ollé Breakdown of academic impact, for papers by Hongli Li Breakdown of academic impact, for papers by Steven Schoenfeld
Rankless by CCL
2026